gesting TPO-producing HCC. (Internal Medicine 42: 730-734, 2003) 
Introduction
Thrombopoietin (TPO), the primary hematopoietic growth factor involved in the regulation of megakaryocyte (MgK) growth and development as well as platelet production has recently been isolated and cloned (1) (2) (3) (4) . Although the complexities of TPO regulation are not fully understood, two possible mechanisms have been postulated. One mechanism is that TPO plasma levels are dependent on the rate of platelet/MgK TPOreceptor (Mpl)-mediated uptake and catabolism (5-7). An elevated platelet level would lead to increased binding and catabolism of TPO to platelet/MgK receptors and consequently a decreased plasma TPOlevel, thereby limiting MgKproduction which would lead to a decreased production of platelets. The other mechanismis that plasma TPOconcentrations are probably regulated by feedback control at the level of gene expression. McCarty et al (8) showed that TPOmRNAexpression in the bone marrow and spleen is increased in thrombocytopenic animal models.
Sungaran et al (9) demonstrated that in thrombocytopenic humansubjects with aplastic anemia, postchemotherapy marrowaplasia, and immunethrombocytopenia, the stromal cells show marked TPOmRNAexpression, suggesting that TPOmRNAexpression in human bone marrow might be modulated by platelet mass. However, these two mechanisms maynot be mutually exclusive or operate in concert.
To date hepatoblastoma and ovarian carcinoma have been reported to produce TPO. Nickerson et al (10) Despite the increased TPO level, the platelet count was inversely proportional to the serum TPOlevel and gradually decreased to 13.5xlO7ul. Anti-TPO antibody neutralizing TPO activity was negative.
55%neutrophils and 38%lymphocytes and the platelet count was 67.4xlO4/jil. Asparate aminotransferase (AST), and alanine aminotransferase (ALT) were 63 and 19 IU//, respectively. Prothrombin time and activated partial thromboplastin time were in the normal range. Alpha fetoprotein was 1.7 ng/ml. Hepatitis B surface antigen, and anti-hepatitis C antibody were negative. Ultrasonography (US) and computed tomography (CT) (Fig. 1 ) of the abdomen demonstrated multiple liver tumors and the largest one measured 15x11x18 cm in the left lobe. Hepatocellular carcinoma (HCC) was diagnosed by needle biopsy and the background liver demonstrated chronic active hepatitis (non-B, non-C). After he was treated by transcatheter arterial embolization (TAE) of the left hepatic artery, the platelet count was decreased from 67.4x107^1 to 48.0x107jli1.
As an enlargement of HCC was not seen, he was discharged in August 2000. He was readmitted because of abdominal pain in January 2001. As the platelet count increased to 86.7x1OVjul, bone marrow aspiration was performed. All nucleated bone marrowcells were 12.0xl07(il and megakaryocyte (MgK) count was 125/jnl. Bonemarrowspecimenshoweda markedincrease in mature, platelet-producing MgK, negative for tumor cells (Fig. 2) . Platelet aggregation studies to ADPwere normal. Amongthe several kinds of cytokines affecting megakaryocytopoiesis, the serum levels of thrombopoietin (TPO) (12), erythropoietin (EPO), interleukin (IL)-6, transforming growth factor (TGF)-pi and hepatocyte growth factor (HGF) were increased. In particular, the serum TPOlevel was extremely high, 14.73 fmol/ml (normal range 0.40±0.29). With the progression of HCC, the serum TPOlevel continuously increased. However, the platelet count was inversely proportional to serum TPO level. The platelet count gradually decreased to 13.5xlO4/jul, despite the increased TPOlevel, of 38.45 fmol/ml in August (Fig. 3) . Thrombocytopenia caused by disseminated intravascular coagulation (DIC) was denied.
Like TPO, the serum levels of EPO, IL-3 and IL-6 were increased in August, compared with those in March ( Table 1 ). metamorphosis were weakly stained, HCCcells were clearly stained by anti-TPO antibody, suggesting TPO-producing HCC (Figs. 4-6) . As a control, immunohistochemical staining of TPOwas performed using liver tissues of another patient with HCCand liver cirrhosis. HCCcells were negative and hepatocytes were weakly positive (Figs. 7, 8 ). BMmetastasis, apparent splenomegaly and thrombosis due to DIC were not observed.
Discussion
We described a 66-year-old man with HCCand marked thrombocytosis, which is very rare among HCC patients.
After he was treated by TAEof the left hepatic artery, the platelet count decreased from 67.4xlO4/nl to 48.0xl04/|al, and then recovered. Although the serum TPOlevel was not measured, the decreased platelet count could be related to the decreased TPOlevel based on the reduction in mass volume. For examination of thrombocytosis (platelet count 1 10.7x
104/|_il), bone marrowaspirates were obtained. The bone marrow specimen showeda markedincrease in mature, plateletproducing MgK,negative for tumor cells. Several kinds of cytokines affecting megakaryocyto-and thrombocytopoiesis were examined, and a high serum TPO level was noted. With the progression of HCC, the serum TPO level continuously increased. Immunohistochemical staining of TPO was performed using an autopsy liver specimen. Although hepatocytes with fatty metamorphosis were weakly positive, HCC cells were clearly stained by anti-TPO antibody, suggesting TPO-producing HCC (Figs. 4-6) . In situ hybridization of the tumor material to complimentary DNAof TPO was not examined. Table 2 shows platelet counts and plasma levels of endogenous TPO in thrombocytopenic patients (14) . The encoded polypeptides of TPOhave a predicted molecular mass of approximately 35,000 kDa. If TPO consists of a fulllength form, it is possible to convert fmol/ml to pg/ml (2 fmol/mlx35,000=70 pg/ml). However, if the TPO molecule was truncated by proteolysis, the conversion was not correct.
With the progression of HCC,the platelet count was inversely proportional to the serum TPOlevel. The autopsy specimen showed normoplastic BMwith decreased MgK, mainly consisting of immature type (Fig. 9) . The causes of thrombocytopenia in the terminal stage could be attributed to: ® TPO dysfunction, © an increase of cytokines affecting thrombocytopoiesis, or ( The median values of TPOin plasma and serum from normal donors were about 100 pg/ml (^2.9 fmol/ml, if TPOis a full-length form). The patients with chronic liver disease appeared to be of two distinct groups: those with high TPOlevels and those with normal to low values. Values for serum samples averaged 17%higher than the values for plasma samples.
Ryu et al Figure 9 . Autopsy specimen showed normoplastic bone marrow with decreased megakaryocytes, mainly consisting of the immature type (HE stain, x200).
karyocytopoiesis (16, 17) , such as TGF-pl, platelet factor 4 However,they also suggested that an excess of circulating TPOcould lead to the disappearance of Mpl from platelets via catabolism. As TPOproduction was self-supported by HCCin this case, the serum TPOlevel was extremely high. Consequently, it may mimic down-regulation of Mpl.
